Articles related to Allergy & Immunology

The Journal of Internal Medicine stresses that, although the timing of antiviral therapy may significantly slow COVID-19 progression, the study was underpowered to evaluate the therapeutic effect of the drugs and they should continue to be used only in studies, not empirical use.

A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.

Beyond converting to telehealth platforms and limiting in-office visits, the Best Practices Committee of the NCCN shares essential approaches to help mitigate the transmission of COVID-19 among patients with cancer and the health care workers who treat them.

Although timely access to the results of studies evaluating patients with cancer infected with COVID-19 is urgently needed, such evidence is currently very limited. The CCC19 hopes to change all of that.

According to a recent study published in Journal of Infectious Diseases, an analysis of four different coronaviruses (OC43, 229E, HKU1 and NL63) over an 8-year period demonstrated that they were detected in a limited timeframe, from December to April and May, with a peak during January and February.

Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.